Product Information

TRI-NYMYO 28 TABLET is a generic product labeled by Mayne Pharma, priced at $0.1373 per EA under NDC 51862064606. Its NADAC has been published 161 times since Oct 20, 2021.

FDA first approved this application on May 30, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the Norgestimate and Ethinyl Estradiol market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

Price Statistics

The NADAC for TRI-NYMYO 28 TABLET has been published 161 times since Oct 20, 2021, and over the history we have for it it has declined 24.3%. The table below summarizes its recorded NADAC range and movement.

Generic Alternatives

The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 21% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.